Status:
COMPLETED
Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Chronic Kidney Disease
Renal Dialysis
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.
Eligibility Criteria
Inclusion
- Chronic kidney disease patients on hemodialysis
- Hyperphosphatemia
- Written informed consent
Exclusion
- Patients with gastrointestinal surgery or enterectomy
- Severe cardiac disease patients
- Patients with severe constipation or diarrhea
- Patients with a complication of malignant tumors
- Patients with uncontrolled hypertension
- Patients treated with parathyroid intervention
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT00892749
Start Date
May 1 2009
End Date
September 1 2010
Last Update
May 4 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chugoku, Japan
2
Chūbu, Japan
3
Kansai, Japan
4
Kantou, Japan